FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224288355> ?p ?o ?g. }

• W4224288355 endingPage "S43" @default.
• W4224288355 startingPage "S43" @default.
• W4224288355 abstract "Purpose To evaluate short and long-term clinical outcomes after lung transplantation of ECD and DCD lungs that were preserved, recruited and assessed using the OCS Lung System. Methods OCS Lung EXPAND targeted double lungs donors with one or more risk factors: age ≥55, PaO2/FiO2 (PF) ≤ 300 mmHg, expected ischemic time > 6 hours, or DCD donors. Lungs were perfused and ventilated on OCS from procurement until time of transplantation. Lungs were transplanted after OCS perfusion if: PF > 300mmHg, vascular resistance, pulmonary artery pressures or peak airway pressures were within 20% of starting values. Patients were followed for 4 years post-transplant and assessed for incidence of BOS and survival. To benchmark the outcomes, we assessed the relative risk for the development of BOS grade 3 between the EXPAND patients and patients in the control arm of the INSPIRE trial who were transplanted with standard-criteria donor (SCD) lungs using ice preservation without OCS perfusion (N=184). Results 79 out of 91 eligible donor lungs were transplanted in the EXPAND Trial for a utilization rate of 87%. Donor inclusion risk factors for the transplanted patients were as follows: 39% age ≥55, 33% DCD, 32% expected ischemic time > 6 hours, 25% PF ≤ 300 mmHg, and 27% with multiple categories. The incidence of BOS Grade 3 is summarized in the table below. Overall graft survival at 4 years was 87.6% for EXPAND vs. 84.9% for the INSPIRE Control cohort. Patient survival at 4 years was 72.0% for EXPAND vs. 71.9% for the INSPIRE Control cohort. Conclusion OCS Lung resulted in a high utilization rate for ECD and DCD donor lungs for transplantation with similar or better long-term post-transplant clinical outcomes compared to SCD lung transplants preserved on ice. These results provide strong clinical evidence supporting the use of the OCS Lung System in extended-criteria donor lungs to increase donor lung utilization for transplantation. To evaluate short and long-term clinical outcomes after lung transplantation of ECD and DCD lungs that were preserved, recruited and assessed using the OCS Lung System. OCS Lung EXPAND targeted double lungs donors with one or more risk factors: age ≥55, PaO2/FiO2 (PF) ≤ 300 mmHg, expected ischemic time > 6 hours, or DCD donors. Lungs were perfused and ventilated on OCS from procurement until time of transplantation. Lungs were transplanted after OCS perfusion if: PF > 300mmHg, vascular resistance, pulmonary artery pressures or peak airway pressures were within 20% of starting values. Patients were followed for 4 years post-transplant and assessed for incidence of BOS and survival. To benchmark the outcomes, we assessed the relative risk for the development of BOS grade 3 between the EXPAND patients and patients in the control arm of the INSPIRE trial who were transplanted with standard-criteria donor (SCD) lungs using ice preservation without OCS perfusion (N=184). 79 out of 91 eligible donor lungs were transplanted in the EXPAND Trial for a utilization rate of 87%. Donor inclusion risk factors for the transplanted patients were as follows: 39% age ≥55, 33% DCD, 32% expected ischemic time > 6 hours, 25% PF ≤ 300 mmHg, and 27% with multiple categories. The incidence of BOS Grade 3 is summarized in the table below. Overall graft survival at 4 years was 87.6% for EXPAND vs. 84.9% for the INSPIRE Control cohort. Patient survival at 4 years was 72.0% for EXPAND vs. 71.9% for the INSPIRE Control cohort. OCS Lung resulted in a high utilization rate for ECD and DCD donor lungs for transplantation with similar or better long-term post-transplant clinical outcomes compared to SCD lung transplants preserved on ice. These results provide strong clinical evidence supporting the use of the OCS Lung System in extended-criteria donor lungs to increase donor lung utilization for transplantation." @default.
• W4224288355 created "2022-04-26" @default.
• W4224288355 creator A5001013964 @default.
• W4224288355 creator A5002289410 @default.
• W4224288355 creator A5014469653 @default.
• W4224288355 creator A5018557049 @default.
• W4224288355 creator A5030730695 @default.
• W4224288355 creator A5034996987 @default.
• W4224288355 creator A5044755845 @default.
• W4224288355 creator A5045931117 @default.
• W4224288355 creator A5049948542 @default.
• W4224288355 creator A5063604853 @default.
• W4224288355 creator A5073629811 @default.
• W4224288355 creator A5073643897 @default.
• W4224288355 creator A5084623835 @default.
• W4224288355 creator A5085228233 @default.
• W4224288355 date "2022-04-01" @default.
• W4224288355 modified "2023-09-24" @default.
• W4224288355 title "Long-Term Results of the OCS Lung Expand International Trial Using Organ Care System Lung Perfusion System (OCS) in Extended-Criteria Donor (ECD) and Donation After Circulatory Death (DCD) Donor Lungs" @default.
• W4224288355 doi "https://doi.org/10.1016/j.healun.2022.01.097" @default.
• W4224288355 hasPublicationYear "2022" @default.
• W4224288355 type Work @default.
• W4224288355 citedByCount "1" @default.
• W4224288355 countsByYear W42242883552022 @default.
• W4224288355 crossrefType "journal-article" @default.
• W4224288355 hasAuthorship W4224288355A5001013964 @default.
• W4224288355 hasAuthorship W4224288355A5002289410 @default.
• W4224288355 hasAuthorship W4224288355A5014469653 @default.
• W4224288355 hasAuthorship W4224288355A5018557049 @default.
• W4224288355 hasAuthorship W4224288355A5030730695 @default.
• W4224288355 hasAuthorship W4224288355A5034996987 @default.
• W4224288355 hasAuthorship W4224288355A5044755845 @default.
• W4224288355 hasAuthorship W4224288355A5045931117 @default.
• W4224288355 hasAuthorship W4224288355A5049948542 @default.
• W4224288355 hasAuthorship W4224288355A5063604853 @default.
• W4224288355 hasAuthorship W4224288355A5073629811 @default.
• W4224288355 hasAuthorship W4224288355A5073643897 @default.
• W4224288355 hasAuthorship W4224288355A5084623835 @default.
• W4224288355 hasAuthorship W4224288355A5085228233 @default.
• W4224288355 hasConcept C126322002 @default.
• W4224288355 hasConcept C141071460 @default.
• W4224288355 hasConcept C146957229 @default.
• W4224288355 hasConcept C2777714996 @default.
• W4224288355 hasConcept C2781448352 @default.
• W4224288355 hasConcept C2911091166 @default.
• W4224288355 hasConcept C2994510829 @default.
• W4224288355 hasConcept C71924100 @default.
• W4224288355 hasConceptScore W4224288355C126322002 @default.
• W4224288355 hasConceptScore W4224288355C141071460 @default.
• W4224288355 hasConceptScore W4224288355C146957229 @default.
• W4224288355 hasConceptScore W4224288355C2777714996 @default.
• W4224288355 hasConceptScore W4224288355C2781448352 @default.
• W4224288355 hasConceptScore W4224288355C2911091166 @default.
• W4224288355 hasConceptScore W4224288355C2994510829 @default.
• W4224288355 hasConceptScore W4224288355C71924100 @default.
• W4224288355 hasIssue "4" @default.
• W4224288355 hasLocation W42242883551 @default.
• W4224288355 hasOpenAccess W4224288355 @default.
• W4224288355 hasPrimaryLocation W42242883551 @default.
• W4224288355 hasRelatedWork W1986842757 @default.
• W4224288355 hasRelatedWork W2033140325 @default.
• W4224288355 hasRelatedWork W2092325412 @default.
• W4224288355 hasRelatedWork W2318299045 @default.
• W4224288355 hasRelatedWork W2417519090 @default.
• W4224288355 hasRelatedWork W2471678635 @default.
• W4224288355 hasRelatedWork W3031286556 @default.
• W4224288355 hasRelatedWork W3141986935 @default.
• W4224288355 hasRelatedWork W4229917249 @default.
• W4224288355 hasRelatedWork W4241758697 @default.
• W4224288355 hasVolume "41" @default.
• W4224288355 isParatext "false" @default.
• W4224288355 isRetracted "false" @default.
• W4224288355 workType "article" @default.